Detalles de la búsqueda
1.
The Utility of Novel Urinary Biomarkers in Mice for Drug Development Studies.
Int J Toxicol
; 40(1): 15-25, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33161787
2.
Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies.
Int J Toxicol
; 38(1): 12-22, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30673360
3.
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Lancet
; 386(10002): 1472-83, 2015 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26210642
4.
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Circ Res
; 112(11): 1479-90, 2013 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-23542898
5.
Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Nucleic Acid Ther
; 26(2): 111-7, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26959999
6.
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
Mol Ther Nucleic Acids
; 5: e317, 2016 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27138177
7.
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Nucleic Acid Ther
; 26(6): 372-380, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27500733
8.
Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.
Mol Ther Nucleic Acids
; 4: e218, 2015 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25602582
9.
Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC-MS/MS.
Bioanalysis
; 4(17): 2141-52, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23013396
10.
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
J Pharmacol Exp Ther
; 321(1): 308-17, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17204749
11.
Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.
Br J Clin Pharmacol
; 61(2): 200-10, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16433874
12.
Disposition of [14C]ruboxistaurin in humans.
Drug Metab Dispos
; 34(11): 1909-17, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16896067
13.
In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy.
Drug Metab Dispos
; 34(2): 213-24, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16258078
Resultados
1 -
13
de 13
1
Próxima >
>>